drugset
drugset / Trial / NCT05269316

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

NCT05269316 ↗

Phase 1/2 Recruiting 61 enrolled Impact Therapeutics, Inc.
NaSequentialOpen-labelTreatment

Summary

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors

Timeline

Start
2022-02-11
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject IMP9064 Protein / enzyme biologic — Oral

Indications

cancer